Esophageal Cancer Market Overview
Esophageal drugs treat esophageal adenocarcinoma, squamous cell carcinoma, and other types. Esophageal cancer affects the cell lining of the esophagus. esophageal cancer market is projected to reach USD 2.20 billion at CAGR of 8.22% by 2030. The symptoms of this disease are difficulty in swallowing food, chest pain, worst digestion, heartburn, coughing and untimely weight loss. The drugs used to treat esophageal cancer and those approved by food and drug administration are docetaxel, trifluridine, and tipiracil hydrochloride. There is a drug named pembrolizumab is, an immunotherapy drug it is also used to treat esophageal cancer.
The esophageal cancer market analyses the contemporary trends, consumer behavior, key player, product strategies driving factors etc. The market overview presented in this report is based on established companies, several sources, industry brokers, trade and industry associations, government organizations and other regulatory and non-regulatory figures. The information collected from these organizations authenticates the Esophageal Cancer Market Growth report, which helps clients to make more confirmed decisions.
Esophageal Cancer Market Report Scope and Segmentation
|UNIT||Value (USD Million/Billion)|
|BY REGION||North America, Europe, Asia Pacific, Latin America, Middle East and Africa|
The COVID pandemic affected everyone’s life and various types of market out there. There was a higher risk of catching COVID-19 infection to cancer patients having severe morbidity and mortality. The main things that challenged the treatment pathway of patients are the complexity of the multidisciplinary approach to esophageal cancer patients and the high morbidity rates of surgery. The surgery of the patients who have cancer was limited mostly due to the lack of anesthesiologists and occupation of intensive care unit beds from canulation patients of COVID-19. Application for neoadjuvant chemo (radio) therapy was increased in 14% of patients. In this way, covid impacted the esophageal cancer market.
- Key drivers
The rise in research and development and the launching of new products by key players are the significant reason which is expected to drive the esophageal cancer market. Increasing research of the new drug discovery for the treatment of esophageal cancer is estimated to drive the market size significantly. The government of several economies and various non-government organizations are taking steps to increase awareness among patients about esophageal cancer. Research regarding esophageal cancer has recently caught the attention of oncologists and experts. The large scale of disease types associated with esophageal cancer is behind the revitalized interest of the medical association. The increased consumption of carcinogens present in specific foods has also become a major concern for oncologists. Therefore, the growth of the esophageal cancer market globally depends on the efforts taken by the medical organization to reduce the occurrence of esophageal cancer.
The major risk factors that cause esophageal cancer include age, gender, achalasia, alcohol, Barrett’s esophagus, obesity, and tobacco. These factors increase the demand for esophageal cancer drugs over the estimated period. According to the study published in National Center for Biotechnology Information in 2017, the general population the achalasia patients have a 50 times more risk of esophageal squamous cell carcinoma. The overall predominance of achalasia is 9 to 10 in 1lakh people annually worldwide.
- Market Challenges
- Expensive Esophageal Cancer Treatment
This major factor is reflected as a challenge in the market. The high cost of the treatments will hamper the Esophageal Cancer Market Value. As it is expensive, most of the population will face a crisis to afford it. This results in affecting the market.
- Side Effects Caused by Esophageal Cancer Treatment Drugs
The side effects begun by drugs are loss of hunger, weakness, weight loss, diarrhea, sore mouth, hair loss, low blood cell counts, hand-foot syndrome, blood clots (, heart damage and nervous system damage. The drugs like Cisplatin, Axalipatin, docetaxel and paclitaxel cause damage to the spinal cord and brain. This adversely affects the esophageal cancer market.
- Market Opportunities
The opportunities that will be received by the Esophageal Cancer Market Forecast period are the commercial market will be evaluated for opportunities related to cancer drugs. It synthesis the insight for business development and licensing. It develops an in-depth knowledge of competition and markets. It helps in developing tactics and strategies to take advantage of the opportunity in the market. It helps in the development of forecast models, healthcare frameworks or economic models.
- Market restraints
The high cost of therapy required for the treatment of esophageal cancer is expected to restrain the esophageal cancer market growth. As per the report published in Health day, cancer patients got treated with US$ 54,100 per in the year 1995, but in 2013, US$ 207,000 per year for the treatment and medications,
The side effects caused due to esophageal cancer drugs are loss of hunger, weight loss, fatigue, diarrhea, loss of hair, sore mouth, hand-foot syndrome, low blood cell counts, blood clots, nervous system damage, and heart damage. According to the 2017 report of the American Cancer Society (ACS), side effects of esophageal cancer drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel give major damage to nerves outside the brain.
The esophageal cancer market is expected to rise its market growth in the estimated period of 2020 to 2027 globally. According to the analyses, the market is growing at a healthy CAGR in the abovementioned research. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market.
The growth of the esophageal cancer market is enhanced by the rise in esophageal cancer cases, which created an opportunity for the pharmaceutical companies to introduce therapy and promising pipeline drugs. The advance in the treatment rate and adoption of inactive lifestyles are some of the factors affecting the demand for esophageal cancer drugs. The product recalls it coupled with a shortage of drugs are the factors that affect the Esophageal Cancer Market Share.
The esophageal cancer market is segmented on the basis of type globally. Based on the type, the market is segmented as esophageal squamous-cell carcinoma, esophageal adenocarcinoma and others. Based on the phases, the market has been segmented as phase 1, phase 2 and phase 3. Based on treatment, the market is segmented by chemotherapy, surgery, radiotherapy, and others.
North America is predicted to dominate the global esophageal cancer market during the estimated period, owing to the high prevalence of esophageal cancer in this region. For instance, according to the American Cancer Society’s report, it projected that around 17,650 new esophageal cancer cases would be diagnosed (13,750 in men and 3,900 in women) in the U.S. by 2019.
The Asia Pacific is expected to have rapid growth in the esophageal cancer market during the estimated period, owing to the rise in clinical trials conducted in Asian countries for drugs to treat esophageal cancer. In Tokyo, National Cancer Center Hospital started a clinical trial in December 2018, which rated the comparative study between combination therapy with induction DCF versus definitive chemo-radiotherapy for locally advanced carcinoma of the thoracic esophagus. These are the Esophageal Cancer Market analysis based on region.
Competitive Intensity Within The Industry
A complete company profile, along with the data related to the production graph, product offerings, and revenue considered by each company, is written within the report. It also reveals the details of Esophageal Cancer Market Trends followed and the gross margins recorded by each manufacturer in the merger with the market share over the estimated period. Some of the main market players are Amgen Inc., Eli Lilly and Company, Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech Inc., Sanofi-Aventis, Merck & Co.
Recent Market Developments
Imugene announced a new clinical trial collab and agreement for supply with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to rate the safety and efficiency of Imugene’s HER-Vaxx, B-cell activating immunotherapy, in combination with MSD’s anti-PD-1 therapy, pembrolizumab in patients with positive gastric cancer.
- Esophageal Squamous-Cell Carcinoma
- Esophageal Adenocarcinoma
By Treatment Type
- Targeted Therapy
Route of Administration
|Market Size||USD 2.20 billion|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||By Type, Phases, Treatment|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Amgen, Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Merck & Co.|
|Key Market Opportunities||Favorable reimbursement scenario and greater expenditure on healthcare In US|
|Key Market Drivers||disordered and deregulated cellular and stromal explosion along with reduced cell deat|